The SANAD II Study of the Effectiveness and Cost-Effectiveness of Valproate Versus Levetiracetam for Newly Diagnosed Generalised and Unclassifiable Epilepsy: An Open-Label, Non-Inferiority, Multicentre, Phase 4, Randomised Controlled Trial
Lancet 397:1375-1386, Marson, A.,et al, 2021
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age with Epilepsy
JAMA Neurol 76:783-790, Kim, H.,et al, 2019
Risk of 23 Specific Malformations Associated with Prenatal Exposure to 10 Antiepileptic Drugs
Neurol 93:e167-e180, Blotiere, P.O.,et al, 2019
Declining Malformation Rates with Changed Antiepileptic Drug Prescribing, An Observational Study
Neurol 93:e831-e840, Tomson,T.,et al, 2019
Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood Autism
JAMA 309:1696-1703, Christensen, J.,et al, 2013
Child Development Following In Utero Exposure: Levetiracetam vs Sodium Valproate
Neurol 76:383-389, Shallcross,R.,et al, 2011
Fetal Effects of Anticonvulsant Polytherapies
Arch Neurol 68:1273-1279, Holmes, L.et al, 2011
Valproic Acid Monotherapy in Pregnancy and Major Congenital Malformations
NEJM 362:2185-2193, Jentink,J., et al, 2010
Malformation Risks of Antiepileptic Drugs in Pregnancy: A Prospective Study from the UK Epilepsy and Pregnancy Register
JNNP 77:193-198,145, Morrow,J.,et al, 2006
In Utero Antiepileptic Drug Exposure: Fetal Death and Malformations
Neurol 67:407-412, Meador,K.J.,et al, 2006
Management Issues for Women with Epilepsy,A Review of the Literature
Neurol 51:949-956, Zahn,C.A.,et al, 1998
Analysis of Prenatal and Gestational Care Given to Women with Epilepsy
Neurol 51:1039-1045, Seale,C.G.,et al, 1998
Practice Parameter,Management Issues for Women with Epilepsy (Summary Statement)
Neurol 51:944-948, Rpt of the Quality Stnds Subcmte AAN, 1998
Epilepsy in Women of Childbearing Age, If Anticonvulsants Cannot be Avoided Use Carbamazepine
BMJ 298:581, Saunders,M., 1989
Plasma Anticonvulsant Concentrations During Pregnancy
Neurol 27:128, Lander,C.M.,et al, 1977